# Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Gastrointestinal Bleeding and Acute Kidney Injury

> **NCT07252401** · NA · NOT_YET_RECRUITING · sponsor: **General Hospital of Shenyang Military Region** · enrollment: 64 (estimated)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **DRUG:** 2-4 mg of terlipressin
- **DRUG:** 3 mg of somatostatin

## Key facts

- **NCT ID:** NCT07252401
- **Lead sponsor:** General Hospital of Shenyang Military Region
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-25
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07252401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07252401, "Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Gastrointestinal Bleeding and Acute Kidney Injury". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07252401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*